export const subject = "Subject Line: Unlock the Potential of CAMZYOS\u00ae in Treatment"

export const preheader = "Preheader: Discover how CAMZYOS\u00ae achieves significant improvements in LVOT gradients compared to placebo."

export const closing = "For additional information about CAMZYOS\u00ae or if you require further assistance, please feel free to reach out. Your inquiries are important to us, and we look forward to supporting your needs."

export const opening = "We would like to provide you with relevant information regarding CAMZYOS\u00ae. This communication aims to enhance your understanding of the product and its applications."

export const hero_image = "https://dcig2tjncq0v8.cloudfront.net/dev/newton/images/8a5cd7df-6afe-425f-962d-3d86376a9a19.png"


export const Non_Claim = [
  {
    "id": 12274,
    "text": "CAMZYOS\u00ae was observed to achieve outcomes on primary and secondary endpoints that differed from those seen with placebo"
  },
  {
    "id": 12275,
    "text": "Study results recorded that patients receiving CAMZYOS\u00ae and those on placebo showed contrasting data for all measured endpoints"
  },
  {
    "id": 12276,
    "text": "CAMZYOS\u00ae was compared with placebo and measured across all prespecified primary and secondary study endpoints"
  },
  {
    "id": 12277,
    "text": "Analysis recorded differences between CAMZYOS\u00ae treatment and placebo in outcomes related to primary and secondary endpoints"
  },
  {
    "id": 12294,
    "text": "Patients receiving CAMZYOS\u00ae exhibited lower resting LVOT gradients over the study duration compared to those on placebo."
  },
  {
    "id": 12295,
    "text": "The Valsalva LVOT gradient measures indicated a consistent decrease in patients taking CAMZYOS\u00ae relative to placebo."
  },
  {
    "id": 12296,
    "text": "Data demonstrate a steady decline in LVOT gradients for CAMZYOS\u00ae patients throughout the treatment period."
  },
  {
    "id": 12297,
    "text": "Results reflect a distinct differentiation in LVOT gradient measurements between CAMZYOS\u00ae and placebo groups across time points."
  },
  {
    "id": 12282,
    "text": "NT-proBNP levels decreased significantly in patients treated with CAMZYOS\u00ae compared to placebo over the study period."
  },
  {
    "id": 12283,
    "text": "hs-cTnI levels in CAMZYOS\u00ae recipients showed a decline, contrasting with stable levels in the placebo group."
  },
  {
    "id": 12284,
    "text": "Observations indicated ongoing reductions in both biomarkers throughout the treatment duration, reflecting consistent responses."
  },
  {
    "id": 12285,
    "text": "Data illustrate the differences in cardiac biomarker levels, reinforcing the findings associated with CAMZYOS\u00ae."
  },
  {
    "id": 12286,
    "text": "Modest reductions in mean global left ventricular systolic function were recorded with time across patient groups."
  },
  {
    "id": 12287,
    "text": "LVEF measurements showed a gradual decline in both Mavacamten and placebo groups over the study duration."
  },
  {
    "id": 12288,
    "text": "Data indicates a near-equal trend in left ventricular function between treatment and control participants."
  },
  {
    "id": 12289,
    "text": "Variability in LVEF percentages was noted, reflecting overall stability in systolic function during the trial."
  },
  {
    "id": 12290,
    "text": "Adverse event rates observed with CAMZYOS were comparable to those recorded with placebo in clinical studies"
  },
  {
    "id": 12291,
    "text": "The most commonly recorded adverse reactions with CAMZYOS occurred at a frequency similar to placebo"
  },
  {
    "id": 12292,
    "text": "Discontinuation rates due to adverse reactions were observed to be similar between CAMZYOS and placebo groups"
  },
  {
    "id": 12293,
    "text": "No new safety signals were identified with CAMZYOS compared to placebo during clinical evaluation"
  },
  {
    "id": 12298,
    "text": "CAMZYOS patients met the primary endpoint at a rate of 37%, compared to 17% in the placebo group."
  },
  {
    "id": 12299,
    "text": "The difference in response rates between CAMZYOS and placebo was statistically significant, with a p-value of 0.0005."
  },
  {
    "id": 12300,
    "text": "Data from Composite 1 indicates a higher percentage of CAMZYOS patients showing improvement in both pVO2 and NYHA class."
  },
  {
    "id": 12301,
    "text": "Composite 2 results further demonstrate the efficacy of CAMZYOS compared to placebo in achieving defined functional thresholds."
  },
  {
    "id": 12278,
    "text": "Post-exercise peak LVOT gradient decreased from 86 mm Hg to 38 mm Hg with CAMZYOS\u00ae."
  },
  {
    "id": 12279,
    "text": "Data demonstrated a clear difference between CAMZYOS\u00ae and placebo measurements."
  },
  {
    "id": 12280,
    "text": "The recorded gradient values indicate a notable change following treatment with CAMZYOS\u00ae."
  },
  {
    "id": 12281,
    "text": "Results suggest consistent outcomes through the treatment period, as observed in the provided data."
  }
]



export const Claim = [
  {
    "id": 3242,
    "text": "Treatment with CAMZYOS\u00ae , a first - in - class cardiac myosin inhibitor , was superior to placebo for all primary and secondary endpoints."
  },
  {
    "id": 3247,
    "text": "Patients given CAMZYOS\u00ae showed rapid and sustained improvement in resting LVOT gradients compared with placebo"
  },
  {
    "id": 3244,
    "text": "Decreases in cardiac biomarkers were rapid and sustained with CAMZYOS\u00ae"
  },
  {
    "id": 3245,
    "text": "Only modest reductions in mean global left ventricular systolic function were observed"
  },
  {
    "id": 3246,
    "text": "CAMZYOS\u00ae was generally well tolerated and the safety profile was similar to placebo"
  },
  {
    "id": 3248,
    "text": "EXPLORER-HCM: 37% of CAMZYOS patients vs 17% of placebo patients met the primary endpoint"
  },
  {
    "id": 3243,
    "text": "Peak post-exercise LVOT gradient decreased from 86 mm Hg to 38 mm Hg with CAMZYOS\u00ae"
  }
]
export const html = 
`<html lang=\"en\">\n<head>\n<meta charset=\"utf-8\"/>\n<meta content=\"width=device-width, initial-scale=1.0\" name=\"viewport\"/>\n<title>CAMZYOS Email Template</title>\n<style>\n * {\n margin: 0;\n padding: 0;\n box-sizing: border-box;\n }\n\n body {\n font-family: Arial, sans-serif;\n line-height: 27px;\n color: #333;\n max-width: 800px;\n margin: 0 auto;\n }\n\n /* \u26a0\ufe0f Warning banner styles */\n .warning-banner {\n display: flex;\n align-items: center;\n background-color: #FFF4E5;\n border-bottom: 2px solid #ffa726;\n /* border-left: 6px solid #f57c00; */\n padding: 16px ;\n margin-top: 10px;\n font-size: 12px;\n color: #000;\n font-family: Arial, sans-serif;\n border-radius: 4px;\n box-shadow: 0 1px 2px rgba(0, 0, 0, 0.1);\n }\n\n .warning-icon {\n font-weight: bold;\n color: #f57c00;\n margin-right: 12px;\n font-size: 24px;\n flex-shrink: 0;\n }\n\n /* Header styles */\n .header-banner {\n background: linear-gradient(90deg, #4a3d69 0%, #b3855f 50%, #4a3d69 100%);\n height: 60px;\n width: 100%;\n margin-bottom: 20px;\n }\n\n .logo-container {\n text-align: right;\n }\n\n .logo {\n max-width: 200px;\n height: auto;\n }\n\n .content {\n padding: 20px;\n }\n\n .greeting {\n font-size: 16px;\n margin-bottom: 20px;\n }\n\n .main-text {\n margin-bottom: 30px;\n }\n\n .module {\n border: 1px dashed #ffd1b3;\n padding: 10px;\n margin: 12px 0;\n border-radius: 5px;\n background-color: #fff9f5;\n }\n\n .module-header {\n display: inline-block;\n font-size: small;\n background-color: #ffe4d1;\n padding: 5px 15px;\n border-radius: 3px;\n margin-right: 10px;\n }\n\n .rating {\n text-align: center;\n margin: 40px 0;\n }\n\n .rating-title {\n margin-bottom: 20px;\n font-size: 18px;\n }\n\n .stars {\n display: flex;\n justify-content: center;\n gap: 20px;\n }\n\n .star {\n color: #ccc;\n font-size: 24px;\n }\n\n .star-number {\n display: block;\n font-size: 14px;\n margin-top: 5px;\n color: #666;\n }\n\n .footer {\n font-size: 14px;\n line-height: 1.8;\n color: #333;\n margin-top: 20px;\n background-color: #fff;\n }\n\n .footer p {\n margin-bottom: 15px;\n }\n\n .footer-links {\n display: flex;\n justify-content: center;\n gap: 20px;\n margin: 20px 0;\n }\n\n .footer-links a {\n color: #4a3d69;\n text-decoration: none;\n }\n\n .footer a:hover {\n text-decoration: underline;\n }\n\n .footer-contact {\n text-align: center;\n margin: 15px 0;\n font-size: 13px;\n }\n\n .footer-id {\n text-align: center;\n color: #666;\n font-size: 12px;\n margin-top: 15px;\n }\n\n .placeholder,\n .placeholder-head {\n color: #666;\n background-color: #f9f9f9;\n padding: 10px;\n margin: 10px 0;\n border: 1px solid #eee;\n }\n\n .hero-placeholder {\n background: #f0f4f8;\n height: 150px;\n display: flex;\n align-items: center;\n justify-content: center;\n border: 2px dashed #cbd5e0;\n margin: 0 0 10px 0;\n border-radius: 4px;\n }\n\n .signature {\n margin: 30px 0;\n }\n\n .references {\n margin-top: 20px;\n }\n </style>\n</head>\n<body style=\"max-width: 700px; font-size: 16px; font-family: Trebuchet MS, sans-serif;\">\n<!-- \u26a0\ufe0f Warning Banner -->\n<div class=\"references\" style=\"padding: 14px 0px;\">\n<div class=\"warning-banner\" id=\"warning\" style=\"display:none\">\n</div>\n<div id=\"subject_line\">Subject Line: Key Insights on CAMZYOS<sup>\u00ae</sup> Efficacy</div>\n<div id=\"preview\">Preheader: Discover how CAMZYOS<sup>\u00ae</sup> significantly reduced LVOT gradient in patients, improving outcomes and understanding.</div>\n</div>\n<div class=\"logo-container\">\n<img alt=\"Brand Logo\" class=\"logo\" src=\"https://dpk6aqf0l5f4n.cloudfront.net/prod/newton/templates/Camzyos_logo.png\"/>\n</div>\n<div>\n<div id=\"hero_image\"><img alt=\"\" src=\"https://dcig2tjncq0v8.cloudfront.net/dev/newton/images/8315ad20-e7ed-4c1f-ad25-67b29e120363.png\" style=\"width: 100%;\" width=\"\"/></div>\n<div id=\"aiDisclaimer\" style=\"text-align: right; font-size: 10px; font-style: italic; font-family: 'Trebuchet MS', sans-serif; color: #555; margin-top: -5px\">Disclaimer: This image is generated using GenAI</div>\n<div class=\"greeting\">Dear {{customText(50)}}</div>\n<div id=\"intro\">CAMZYOS<sup>\u00ae</sup> is a key focus in ongoing efforts to address specific patient needs. This communication outlines pertinent information to enhance awareness and understanding of CAMZYOS<sup>\u00ae</sup>.</div>\n<div id=\"module\"><div style=\"margin: 12px 0px;\">\n<div data-claim-id=\"3242\" id=\"claim_3242\" style=\"color: #34495e; font-size: 17px; margin-bottom: 15px; font-weight: 900; border-bottom: 1px solid red; padding-bottom: 7px; text-align: justify;\">\n Treatment with CAMZYOS<sup>\u00ae</sup> , a first - in - class cardiac myosin inhibitor , was superior to placebo for all primary and secondary endpoints.<sup>1</sup>\n</div>\n<ul style=\"list-style-type: disc; padding-left: 8px;\">\n<li data-nonclaim-id=\"12274\" id=\"nonclaim_12274\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n CAMZYOS<sup>\u00ae</sup> was observed to achieve outcomes on primary and secondary endpoints that differed from those seen with placebo\n </li>\n<li data-nonclaim-id=\"12275\" id=\"nonclaim_12275\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Study results recorded that patients receiving CAMZYOS<sup>\u00ae</sup> and those on placebo showed contrasting data for all measured endpoints\n </li>\n<li data-nonclaim-id=\"12276\" id=\"nonclaim_12276\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n CAMZYOS<sup>\u00ae</sup> was compared with placebo and measured across all prespecified primary and secondary study endpoints\n </li>\n<li data-nonclaim-id=\"12277\" id=\"nonclaim_12277\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Analysis recorded differences between CAMZYOS<sup>\u00ae</sup> treatment and placebo in outcomes related to primary and secondary endpoints\n </li>\n</ul>\n</div><div style=\"margin: 12px 0px;\">\n<div data-claim-id=\"3247\" id=\"claim_3247\" style=\"color: #34495e; font-size: 17px; margin-bottom: 15px; font-weight: 900; border-bottom: 1px solid red; padding-bottom: 7px; text-align: justify;\">\n Patients given CAMZYOS<sup>\u00ae</sup> showed rapid and sustained improvement in resting LVOT gradients compared with placebo<sup>1</sup>\n</div>\n<ul style=\"list-style-type: disc; padding-left: 8px;\">\n<li data-nonclaim-id=\"12294\" id=\"nonclaim_12294\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Patients receiving CAMZYOS<sup>\u00ae</sup> exhibited lower resting LVOT gradients over the study duration compared to those on placebo.\n </li>\n<li data-nonclaim-id=\"12295\" id=\"nonclaim_12295\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n The Valsalva LVOT gradient measures indicated a consistent decrease in patients taking CAMZYOS<sup>\u00ae</sup> relative to placebo.\n </li>\n<li data-nonclaim-id=\"12296\" id=\"nonclaim_12296\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Data demonstrate a steady decline in LVOT gradients for CAMZYOS<sup>\u00ae</sup> patients throughout the treatment period.\n </li>\n<li data-nonclaim-id=\"12297\" id=\"nonclaim_12297\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Results reflect a distinct differentiation in LVOT gradient measurements between CAMZYOS<sup>\u00ae</sup> and placebo groups across time points.\n </li>\n</ul>\n</div><div style=\"margin: 12px 0px;\">\n<div data-claim-id=\"3244\" id=\"claim_3244\" style=\"color: #34495e; font-size: 17px; margin-bottom: 15px; font-weight: 900; border-bottom: 1px solid red; padding-bottom: 7px; text-align: justify;\">\n Decreases in cardiac biomarkers were rapid and sustained with CAMZYOS<sup>\u00ae</sup><sup>1</sup>\n</div>\n<ul style=\"list-style-type: disc; padding-left: 8px;\">\n<li data-nonclaim-id=\"12282\" id=\"nonclaim_12282\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n NT-proBNP levels decreased significantly in patients treated with CAMZYOS<sup>\u00ae</sup> compared to placebo over the study period.\n </li>\n<li data-nonclaim-id=\"12283\" id=\"nonclaim_12283\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n hs-cTnI levels in CAMZYOS<sup>\u00ae</sup> recipients showed a decline, contrasting with stable levels in the placebo group.\n </li>\n<li data-nonclaim-id=\"12284\" id=\"nonclaim_12284\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Observations indicated ongoing reductions in both biomarkers throughout the treatment duration, reflecting consistent responses.\n </li>\n<li data-nonclaim-id=\"12285\" id=\"nonclaim_12285\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Data illustrate the differences in cardiac biomarker levels, reinforcing the findings associated with CAMZYOS<sup>\u00ae</sup>.\n </li>\n</ul>\n</div><div style=\"margin: 12px 0px;\">\n<div data-claim-id=\"3245\" id=\"claim_3245\" style=\"color: #34495e; font-size: 17px; margin-bottom: 15px; font-weight: 900; border-bottom: 1px solid red; padding-bottom: 7px; text-align: justify;\">\n Only modest reductions in mean global left ventricular systolic function were observed<sup>1</sup>\n</div>\n<ul style=\"list-style-type: disc; padding-left: 8px;\">\n<li data-nonclaim-id=\"12286\" id=\"nonclaim_12286\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Modest reductions in mean global left ventricular systolic function were recorded with time across patient groups.\n </li>\n<li data-nonclaim-id=\"12287\" id=\"nonclaim_12287\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n LVEF measurements showed a gradual decline in both Mavacamten and placebo groups over the study duration.\n </li>\n<li data-nonclaim-id=\"12288\" id=\"nonclaim_12288\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Data indicates a near-equal trend in left ventricular function between treatment and control participants.\n </li>\n<li data-nonclaim-id=\"12289\" id=\"nonclaim_12289\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Variability in LVEF percentages was noted, reflecting overall stability in systolic function during the trial.\n </li>\n</ul>\n</div><div style=\"margin: 12px 0px;\">\n<div data-claim-id=\"3246\" id=\"claim_3246\" style=\"color: #34495e; font-size: 17px; margin-bottom: 15px; font-weight: 900; border-bottom: 1px solid red; padding-bottom: 7px; text-align: justify;\">\n CAMZYOS<sup>\u00ae</sup> was generally well tolerated and the safety profile was similar to placebo<sup>2</sup>\n</div>\n<ul style=\"list-style-type: disc; padding-left: 8px;\">\n<li data-nonclaim-id=\"12290\" id=\"nonclaim_12290\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Adverse event rates observed with CAMZYOS were comparable to those recorded with placebo in clinical studies\n </li>\n<li data-nonclaim-id=\"12291\" id=\"nonclaim_12291\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n The most commonly recorded adverse reactions with CAMZYOS occurred at a frequency similar to placebo\n </li>\n<li data-nonclaim-id=\"12292\" id=\"nonclaim_12292\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Discontinuation rates due to adverse reactions were observed to be similar between CAMZYOS and placebo groups\n </li>\n<li data-nonclaim-id=\"12293\" id=\"nonclaim_12293\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n No new safety signals were identified with CAMZYOS compared to placebo during clinical evaluation\n </li>\n</ul>\n</div><div style=\"margin: 12px 0px;\">\n<div data-claim-id=\"3248\" id=\"claim_3248\" style=\"color: #34495e; font-size: 17px; margin-bottom: 15px; font-weight: 900; border-bottom: 1px solid red; padding-bottom: 7px; text-align: justify;\">\n EXPLORER-HCM: 37% of CAMZYOS patients vs 17% of placebo patients met the primary endpoint<sup>2,3</sup>\n</div>\n<ul style=\"list-style-type: disc; padding-left: 8px;\">\n<li data-nonclaim-id=\"12298\" id=\"nonclaim_12298\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n CAMZYOS patients met the primary endpoint at a rate of 37%, compared to 17% in the placebo group.\n </li>\n<li data-nonclaim-id=\"12299\" id=\"nonclaim_12299\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n The difference in response rates between CAMZYOS and placebo was statistically significant, with a p-value of 0.0005.\n </li>\n<li data-nonclaim-id=\"12300\" id=\"nonclaim_12300\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Data from Composite 1 indicates a higher percentage of CAMZYOS patients showing improvement in both pVO2 and NYHA class.\n </li>\n<li data-nonclaim-id=\"12301\" id=\"nonclaim_12301\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Composite 2 results further demonstrate the efficacy of CAMZYOS compared to placebo in achieving defined functional thresholds.\n </li>\n</ul>\n</div><div style=\"margin: 12px 0px;\">\n<div data-claim-id=\"3243\" id=\"claim_3243\" style=\"color: #34495e; font-size: 17px; margin-bottom: 15px; font-weight: 900; border-bottom: 1px solid red; padding-bottom: 7px; text-align: justify;\">\n Peak post-exercise LVOT gradient decreased from 86 mm Hg to 38 mm Hg with CAMZYOS<sup>\u00ae</sup><sup>1</sup>\n</div>\n<ul style=\"list-style-type: disc; padding-left: 8px;\">\n<li data-nonclaim-id=\"12278\" id=\"nonclaim_12278\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Post-exercise peak LVOT gradient decreased from 86 mm Hg to 38 mm Hg with CAMZYOS<sup>\u00ae</sup>.\n </li>\n<li data-nonclaim-id=\"12279\" id=\"nonclaim_12279\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Data demonstrated a clear difference between CAMZYOS<sup>\u00ae</sup> and placebo measurements.\n </li>\n<li data-nonclaim-id=\"12280\" id=\"nonclaim_12280\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n The recorded gradient values indicate a notable change following treatment with CAMZYOS<sup>\u00ae</sup>.\n </li>\n<li data-nonclaim-id=\"12281\" id=\"nonclaim_12281\" style=\"color: black; font-family: Arial; font-size: 16px; line-height: 27px; text-align: start; margin-bottom: 5px;\">\n Results suggest consistent outcomes through the treatment period, as observed in the provided data.\n </li>\n</ul>\n</div></div>\n<div id=\"closing\">For additional information regarding CAMZYOS<sup>\u00ae</sup>, please visit our official website, or reach out with any specific inquiries you may have. We are here to assist you in any way possible.</div>\n<br/>\n<tr>\n<td align=\"left\" class=\"element_kvpu7\" style=\"font-size:0px;padding:10px 25px;padding-right:30px;\">\n<div>{Best Regards}</div>\n<div>{{userName}} {{User.Credentials_}}</div>\n<div>{{userEmailAddress}}</div>\n<div>{{User.MobilePhone}}</div>\n</td>\n</tr>\n<div class=\"references\" style=\"border-top: 1px solid #eee;\">\n<div id=\"footnotes\">\n<div style=\"color: #555555; font-size: 13px;\">NYHA, New York Heart Association; PVO2, peak oxygen consumption.; HCM, hypertrophic cardiomyopathy; HCMSQ-SOB, Hypertrophic Cardiomyopathy Symptom Questionnaire-Shortness of Breath; hs-cTnl, high-sensitivity cardiac troponin; KCCQ-23 CSS, 23-item Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; LVOT, left ventricular outflow tract; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; PVO2, peak oxygen consumption.; HCM, hypertrophic cardiomyopathy.; HCM, hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction.</div>\n</div>\n<div id=\"reference\">\n<div style=\"color: #555555; font-size: 12px;margin-top: 4px; margin-bottom: 16px; text-align: start;\">\n References\n</div>\n<div style=\"padding-left: 15px;\">\n<ol style=\"list-style-type: decimal; padding-left: 20px;\">\n<li style=\"color: #555555; font-family: Arial; font-size: 12px; line-height: 18px; text-align: start; margin-bottom: 5px;\">\n Olivotto | et al. Lancet. 2020;396:759\u2013769.\n </li>\n<li style=\"color: #555555; font-family: Arial; font-size: 12px; line-height: 18px; text-align: start; margin-bottom: 5px;\">\n Olivotto | et al. Lancet. 2020;396:759-769.\n </li>\n<li style=\"color: #555555; font-family: Arial; font-size: 12px; line-height: 18px; text-align: start; margin-bottom: 5px;\">\n CAMZYOS<sup>\u00ae</sup> SmPC.\n </li>\n</ol>\n</div>\n</div>\n</div>\n<div style=\"background-color: #130D2F; height: 2px; width: 100%; margin: 20px 0;\"></div>\n<div style=\"text-align: right; margin-bottom: 20px;\">\n<img alt=\"Camzyos Logo\" src=\"https://dpk6aqf0l5f4n.cloudfront.net/prod/newton/templates/Camzyos_logo.png\" style=\"max-width: 150px; height: auto;\"/>\n</div>\n<footer class=\"footer\" style=\"text-align: justify; font-size: 16px; line-height: 1.6;\">\n<p style=\"margin-bottom: 20px;\">\n<strong>CAMZYOS<sup>\u00ae</sup></strong>(mavakamten) 2.5 mg, 5 mg, 10 mg, 15 mg, hard capsules. Agents for heart disease, Other\n agents for heart disease, ATC code: C01EB24\n <br/>\n<strong>Indication:</strong>CAMZYOS<sup>\u00ae</sup> is indicated for the treatment\n of symptomatic (New York Heart Association, NYHA, functional class II\u2013III) obstructive hypertrophic\n cardiomyopathy (oHCM) in adults.\n <br/>\n<strong>Contraindication:</strong>During pregnancy and to fertile women who do\n not use an effective contraceptive method. ...\n </p>\n<p style=\"text-align: center; margin-bottom: 30px;\">\u00a9 <span id=\"year\"></span> MyoKardia, Inc., a Bristol Myers\n Squibb company. CAMZYOS<sup>\u00ae</sup> and the CAMZYOS Logo are trademarks of MyoKardia, Inc.</p>\n<div style=\"text-align: center; margin-bottom: 30px;\">\n<img alt=\"Bristol Myers Squibb\" src=\"https://dpk6aqf0l5f4n.cloudfront.net/prod/newton/templates/static/496f0545-dedc-4fac-8a8d-1df2c6d6a7a3.png\" style=\"max-width: 200px;\"/>\n</div>\n</footer>\n</div>\n<script>\n document.getElementById(\"year\").textContent = new Date().getFullYear();\n const date = new Date();\n const monthNames = [\n \"JANUARY\", \"FEBRUARY\", \"MARCH\", \"APRIL\", \"MAY\", \"JUNE\",\n \"JULY\", \"AUGUST\", \"SEPTEMBER\", \"OCTOBER\", \"NOVEMBER\", \"DECEMBER\"\n ];\n \n const currentMonth = monthNames[date.getMonth()]; // Get current month in uppercase\n const currentYear = date.getFullYear(); // Get current year\n\n // Update the span with the dynamic month and year\n document.getElementById(\"dynamicDate\").textContent = currentMonth + currentYear;\n</script>\n</body></html>\n`
